References
- 1. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from Major Depressive Disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156:1000-6.10.1176/ajp.156.7.1000
- 2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163:28-40.10.1176/appi.ajp.163.1.28
- 3. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007;8:67-104.10.1080/15622970701227829
- 4. Gabos Grecu I. Actualități în terapia depresiilor, Editura University Press, Tîrgu Mureș, 2007, pp. 116-129.
- 5. Moller HJ. Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. World J Biol Psychiatry. 2008;9:102-14.10.1080/15622970801981606
- 6. Mulder RT, Frampton CM, Luty SE, Joyce PR. Eighteen months of drug treatment for depression: Predicting relapse and recovery. J Affect Disord. 2009;114:263-70.10.1016/j.jad.2008.08.002
- 7. Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance, and public health signifi cance of subthreshold depressions. Psychiatr Clin North Am. 2002;25:685-98.10.1016/S0193-953X(02)00026-6
- 8. McIntyre RS, O'Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry. 2004;49(Suppl 1):10S-16S.
- 9. Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health policy Econ. 2006;9:87-98.
- 10. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatmentresistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007;68:826-831.10.4088/JCP.v68n060217592905
- 11. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord. 2003;5(Suppl 2):20-35.10.1111/j.1399-2406.2003.00061.x14700010
- 12. Adson DE, Kushner MG, Eiben KM, Schulz SC. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety. 2004;19:121-126.10.1002/da.1013715022147
- 13. Yargic LI, Corapcioglu A, Kocabasoglu N, et al. A prospective randomized single-blind, multicenter trial comparing the effi cacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int J Psychiatry Clin Pract. 2004;8(4):205-211.10.1080/1365150041000572024930548
- 14. McIntyre A, Gendron A, McIntyre A. Quetiapine augmentation of SSRIs/ SNRIs in major depression with anxiety. 2006 in Poster presented at: American Psychiatric Association annual meeting, Toronto, Ontario.
- 15. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord. 2010;127(1-3):19-30.10.1016/j.jad.2010.08.03220884063